It’s not particularly unusual to spend eight-hours listening to a US Food and Drug Administration advisory committee poke hole after hole in a sponsor’s data, and then do a bit of a double-take when at the end of the day the majority of the committee votes in favor of the product’s risk-benefit profile.
At first glance it can be a little perplexing, but long-time FDA watchers know that in the world of drug...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?